Navigation Links
Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential
Date:12/10/2009

SAN DIEGO, Dec. 10, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that positive data from a clinical trial evaluating the abuse potential of lorcaserin were presented in a poster session at the 48th Annual Meeting of the American College of Neuropsychopharmacology. Data from the trial demonstrate that the risk for abuse associated with lorcaserin is very low.

"Human abuse liability studies of the type done by Arena provide critical data to the FDA and DEA for decisions about any post-marketing scheduling and control under the Controlled Substance Act," said Edward M. Sellers, M.D., Ph.D., Vice President of Kendle International Inc., and Principal Investigator.

Investigational drugs that act through mechanisms in the brain are generally required to undergo an evaluation to determine abuse potential. This determination will be made by the US Drug Enforcement Administration (DEA), with input from the US Food and Drug Administration (FDA), as part of the regulatory review process. Lorcaserin was studied in a standard paradigm at doses well above the intended therapeutic dose of 10 mg twice daily. The clinical trial compared the relative abuse potential of lorcaserin against three comparators: placebo, zolpidem (a schedule IV controlled substance) and ketamine (a schedule III controlled substance).

The trial was a randomized, placebo-controlled, double-blind, seven-way crossover trial conducted in 35 healthy male and female recreational drug users. Subjects received single doses of lorcaserin (20 mg, 40 mg and 60 mg), zolpidem (15 mg and 30 mg), ketamine (100 mg) and placebo in a blinded fashion. Following dosing, subjects completed tests that assessed their subjective states and the drugs' effects (both positive and negative). The primary endpoint was derived from the scor
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... OAKS, Calif., April 13, 2011 Amgen (NASDAQ: ... first quarter financial results on Wednesday, April 20, 2011 after ... be followed by a conference call with the investment community ... Amgen will be Kevin Sharer, chairman and chief executive officer, ...
... 13, 2011 Perrigo (Nasdaq: PRGO;TASE) today announced that ... TEVA ), has received final OTC approval to sell ... tablets; the generic equivalents of Sanofi-Aventis, Allegra 60 mg ... for these products, and Teva and Sanofi-Aventis have settled ...
Cached Medicine Technology:Amgen Announces Webcast of 2011 First Quarter Financial Results 2Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets 2Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets 3
(Date:7/9/2014)... A retrospective study conducted by researchers at Tufts University ... adults with intellectual and developmental disabilities, the likelihood of ... dental care increased. The findings, published in the July/August ... help improve interventions designed to address the oral health ... reviewed the dental records of 107 patients at one ...
(Date:7/9/2014)... , , , , , ... , , , , ... the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , , ... , , , , , ... , , , , , , University ...
(Date:7/9/2014)... of Medicine of the University of Southern California ... component of the immune system are completely resistant ... The discovery suggests that blocking this immune system ... and hyper-inflammatory diseases such as rheumatoid arthritis and ... online on June 23 in The Journal ...
(Date:7/8/2014)... The Department of Defense,s Defense Advanced Research Projects ... up to $2.5 million to develop an implantable ... stimulate neurons within the brain to help restore ... research builds on the understanding that memory is ... of the brain encode information, store it and ...
(Date:7/8/2014)... In a study published yesterday in the scientific ... Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify new ... affects over 200 million people world wide. , An ... divided into small sections or ,neighborhoods., Scientists can determine ... for gene production, by looking for a marker on the ...
Breaking Medicine News(10 mins):Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:LJI develops new approach to identify genes poised to respond in asthma patients 2
... TORRANCE, Calif., April 27 According to new ... , supplements of Lactobacillus casei strain Shirota may ... fatigue syndrome (CFS). Thirty-nine patients with CFS ... Shirota or placebo for two months. Compared ...
... Services Department declares a Public Health EmergencyHARRISBURG, Pa., April ... working with federal officials to contain the impact of ... in the declaration of a national public health emergency ... to educate the public and health care providers of ...
... toxins in the products we use for lifestyle convenience, ... toxic load on our bodies contributing to chronic illnesses, ... awareness of our environmental exposures, Metametrix Clinical Laboratory ( ... release of three new testing profiles in the Toxic ...
... 100 Exhibits, Forums on Health Care and Financial Security, ... Top Musicians***LOS LOBOS TO HEADLINE ENTERTAINMENT***SAN ANTONIO, April 27 ... for people age 50+, today announced it will bring ... San Antonio on May 15-16. The two-day, cross-generational ...
... screen at 40, but yearly PSA may not be necessary, ... guidelines on prostate cancer screening suggest that annual PSA blood ... same guidelines call for a "baseline" PSA test at the ... (PSA) test to detect early signs of prostate cancer should ...
... WHAT: , Media may now register to attend ... Symposium of the Cardiovascular Research Foundation. TCT gathers ... world to present and discuss the latest developments ... medicine. Now in its 21st year, TCT brings ...
Cached Medicine News:Health News:New Study Shows Supplementing With Probiotics May Ease Anxiety 2Health News:Pennsylvania Working Closely With Federal Partners to Contain Impact of Swine Flu 2Health News:Pennsylvania Working Closely With Federal Partners to Contain Impact of Swine Flu 3Health News:Metametrix Announces New Toxic Effects Profiles to Help Combat Growing Concerns About Toxicity and Health 2Health News:AARP to Host Cross-Generational 'Life Festival' in San Antonio May 15-16 2Health News:AARP to Host Cross-Generational 'Life Festival' in San Antonio May 15-16 3Health News:Experts Back Away From Annual PSA Test 2Health News:Experts Back Away From Annual PSA Test 3Health News:Media registration now open for TCT 2009 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: